Novo Nordisk

Novo Nordisk Shares Surge on Landmark Weight-Loss Pill Approval

December 24, 2025

Novo Nordisk Seeks FDA Approval for Next-Generation Weight Loss Therapy

angelina - December 22, 2025

Novo Nordisk Shares Face Mounting Challenges Amid Competitive and Political Headwinds

Brett Shapiro - December 17, 2025

Novo Nordisk Seeks Momentum with EMA Backing for Higher-Dose Obesity Drug

December 15, 2025

Novo Nordisk Shares Plunge as Weight-Loss Drug Dominance Fades

December 11, 2025

Novo Nordisk Faces Dual Challenges: Counterfeit Drugs and Patent Pressures

December 6, 2025

Novo Nordisk’s Strategic Pivot: A Desperate Gamble or Calculated Move?

angelina - December 3, 2025

Novo Nordisk Shares Face Mounting Headwinds as Key Challenges Converge

Brett Shapiro - December 1, 2025

Novo Nordisk’s Bold Counter-Offensive to Regain Momentum

Brett Shapiro - November 30, 2025

Novo Nordisk Shares Face Market Turbulence Amid Clinical Trial Results

kashif hafeez - November 26, 2025

Novo Nordisk’s Bold Price Strategy: Volume Over Margin in the Weight-Loss Drug Battle

kashif hafeez - November 21, 2025

Novo Nordisk Shares Under Pressure as Price War Intensifies

angelina - November 19, 2025

Governance Crisis Erupts at Novo Nordisk as Foundation Ousts Entire Board

Brett Shapiro - November 15, 2025

Novo Nordisk Shares Plunge Amid Mounting Challenges

angelina - November 9, 2025